(CDAX, Technology, SYT GR)



Buy eur 8.00	(EUR 8.90)	Value Indicators:EUDCF:7.9FCF-Value Potential 26e:7.9		Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.3 3.0 3.8 0.0	Description: Soft- and hardware for data exchange for e.g. industrial plants and automotive electronics		
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2024e	
		Market cap:	50.5	Freefloat	62.60 %	Beta:	1.3	
Price	EUR 5.55	No. of shares (m):	9.1	Trier Asset Mgmt	22.40 %	Price / Book:	0.9 x	
Upside	44.1 %	EV:	70.7	Alois Widmann	15.00 %	Equity Ratio:	49 %	
		Freefloat MC:	31.6			Net Fin. Debt / EBITDA:	1.2 x	
		Ø Trad. Vol. (30d):	14.71 th			Net Debt / EBITDA:	1.4 x	

Margin improvement expected despite challenging economic environment

Stated Figure	es Q4/2	023:							Comment on Figures:
FY End: 31.12. in EUR m	Q4 23	Q4 23e	Q4 22	уоу	23	23e	22	уоу	 Sales driven by the larger segments, Industrial and Automotive Improvement in adj. EBIT mainly attributable to a notable 5pp mainly
Sales EBIT adj.	25.4 -0.1	28.5 0.3	28.4 1.2	-10 % n.a.	112.6 5.6	115.7 6.1	98.3 3.3	15 % 72 %	 improvement in Industrial The reported EBIT included a EUR 6.2m goodwill impairment a consequence of adjustments to the business model in two acqui
Margin EBIT Margin	-0.5 % - 8.3 -32.5 %	1.2 % -7.7 -27.1 %	4.2 % 2.2 7.8 %	n.a.	5.0 % -2.7 -2.4 %	5.3 % -2.2 -1.9 %	3.3 % 0.8 0.8 %	n.a.	subsidiaries

Softing has published 2023 results, which were roughly in line with our estimates and company targets even after several guidance-increases throughout the year. The 15% top-line growth to EUR 113m (target EUR 110-115m) was driven by the two larger segments Industrial (EUR 83m, +15% yoy) and Automotive (EUR 23m, +18%), which benefitted from a catch-up effect after the component shortages. In the smallest segment, IT Networks, revenue declined by 5% to EUR 7.3m despite solid demand, due to supply disruption with a contract manufacturer.

The adj. EBIT of EUR 5.6m increased by 72% yoy. This was mainly the result of high profitability in the largest segment Industrial, which reached an adj. EBIT margin of 12% after 7% last year. In Automotive, the adj. EBIT improved from EUR -1.9m in 2022 to EUR -0.9m. While the core business was profitable, delays in the GlobalmatiX roll-out led to the segment's negative operating result. The adj. EBIT in IT Networks remained roughly stable at EUR -2.6m (2022 EUR -2.4m). Despite the solid operating improvement, the reported EBIT declined from EUR 0.8m to EUR - 2.7m due to a 6.2m goodwill impairment. The non-cash one-off was not a consequence of lower expected returns, but a result of adjustments to the business model in two acquired subsidiaries.

For 2024, Softing is expecting sales of EUR 105-113m and an adj. EBIT of EUR 5-7m, which is below our expectations. While growth should be driven by the planned GlobalmatiX roll-out, the major contract announced in December (Automotive) and the resolution of the supply issues (IT Networks) in the respective segments, this might not fully compensate for the economic headwinds in the Industrial segment. However, the visibly positive development expected in Automotive and IT Networks should notably improve the profitability in those segments and result in adj. EBIT growth despite the anticipated top-line decline. We adjusted our forecast and confirm our Buy recommendation with our new PT of EUR 8.


Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2024e (old)	+ / -	2025e (old)	+ / -	2026e (old)	+ / -	2024 figures adjusted in accordance with the guidanceThe lower profitability estimates are a result of the reduced sales volume
Sales	121.3	-9.6 %	129.2	-9.5 %	n.a.	n.m.	and a lower sales-contribution from the most profitable segment,
EBIT	7.3	-44.6 %	8.9	-39.5 %	n.a.	n.m.	Industrial
EBIT adj.	8.3	-24.7 %	10.2	-31.6 %	n.a.	n.m.	

7.5 7.25 Multure		FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
7- 1 1 1	~	Sales	3.0 %	77.6	84.7	98.3	112.6	109.7	116.9	122.9
6.75 -	M	Change Sales yoy		-14.8 %	9.1 %	16.1 %	14.5 %	-2.6 %	6.6 %	5.1 %
6.5 - L W Wh m.m	m may	Gross profit margin		59.5 %	58.2 %	54.9 %	59.0 %	58.5 %	58.6 %	58.3 %
6.25 - Smarty Martin also 1	~~	EBITDA	5.8 %	7.8	9.1	9.7	13.9	14.4	15.6	16.5
		Margin		10.0 %	10.7 %	9.9 %	12.4 %	13.2 %	13.3 %	13.4 %
6 - William 1	1.00	EBIT	-	-3.9	-0.5	0.8	-2.7	4.0	5.4	6.5
5.75 - V	Art and Met	Margin		-5.1 %	-0.6 %	0.8 %	-2.4 %	3.7 %	4.6 %	5.3 %
5.5 -		EBIT adj.	12.2 %	1.6	3.0	3.3	5.6	6.2	7.0	8.0
5.25 -	•	Net income	-	-4.7	-0.3	-1.4	-5.8	2.2	3.1	3.9
	01/24 03/24	EPS	-	-0.52	-0.03	-0.15	-0.65	0.25	0.34	0.43
Softing CDAX (normalised	1)	DPS	0.0 %	0.04	0.10	0.10	0.13	0.13	0.13	0.13
Rel. Performance vs CDAX	•	Dividend Yield		0.7 %	1.6 %	1.7 %	2.0 %	2.3 %	2.3 %	2.3 %
		FCFPS		-0.38	0.42	-0.40	-0.04	1.05	0.33	0.45
1 month:	-1.7 %	FCF / Market cap		-6.5 %	6.9 %	-6.7 %	-0.6 %	18.7 %	6.0 %	8.1 %
6 months:	-28.8 %	EV / Sales		0.9 x	0.8 x	0.8 x	0.7 x	0.6 x	0.6 x	0.6 x
Year to date:	-4.4 %	EV / EBITDA		9.0 x	7.7 x	7.7 x	5.9 x	4.9 x	4.5 x	4.2 x
Trailing 12 months:	-22.2 %	EV / EBIT adj.		44.8 x	23.2 x	23.0 x	14.6 x	11.3 x	10.1 x	8.8 x
5		EV / EBIT		n.a.	n.a.	98.7 x	n.a.	17.5 x	13.1 x	10.8 x
Company events:		P/E		n.a.	n.a.	n.a.	n.a.	22.2 x	16.3 x	12.9 x
07.05.24	Q1	FCF Potential Yield		4.8 %	6.2 %	6.1 %	6.7 %	8.9 %	9.7 %	10.6 %
08.05.24	AGM	Net Debt		17.5	14.0	21.5	24.8	20.1	20.3	19.4
14.08.24	Q2	ROCE (NOPAT)		n.a.	0.1 %	2.0 %	n.a.	3.6 %	4.9 %	5.9 %
15.11.24	Q3	Guidance:	Sales EUR 10)5-113m, adj.	EBIT EUR 5	.0-7.0m. EBI	T EUR 3.2-4	-6m		
Analyst										

Analyst **Robert-Jan van der Horst** rvanderhorst@warburg-research.com +49 40 309537-290

WARBURG

Softing




Company Background

- Softing has the necessary expertise on information exchange between various devices, sensors, plant and software solutions in automated processes. Its business activity comprises three segments.
- Industrial Automation: hardware and software solutions for the exchange of information in all kinds of production including assembly lines, chemical plants, oil and gas extraction or refineries.
- IT Networks: diagnostic devices which are used in industrial automation and for the diagnosis of copper and optical fibre networks in data centers and office installations
- Automotive Electronics: The solutions allow engineers and workshop mechanics to test automotive electronics in the development phase, production or repair and to recognise errors via data evaluation.
- The solutions in the automotive segment are not for application within the vehicles and therefore do not pose a product re-call risk for the company.

Competitive Quality

- European market leader in the networking of various production plant elements as well as in business-related software (so-called OPC products).
- World market leader in components for the exchange of information in gas and oil plants. Some >50% of all devices registered worldwide that are used in these plants include components from Softing.
- Softing's participation in international committees that set standards for the exchange of information. This contributes to a short timeto-market.
- The high complexity of Softing's business activity is the single most important barrier to market entry for potential competitors.





DCF model Transitional period Term. Value Detailed forecast period Figures in EUR m 2024e 2025e 2026e 2027e 2028e 2029e 2030e 2031e 2032e 2033e 2034e 2035e 2036e Sales 109.7 116.9 122.9 128.8 134.7 140.5 146.3 152.0 157.7 163.2 168.7 174.1 177.5 Sales change -2.6 % 6.6 % 5.1 % 4.8 % 4.6 % 4.3 % 4.1 % 3.9 % 3.7 % 3.5 % 3.4 % 3.2 % 2.0 % 2.0 % EBIT 4.0 5.4 6.5 8.1 9.1 9.5 9.9 10.2 10.6 11.0 11.3 11.5 7.1 EBIT-margin 3.7 % 4.6 % 5.3 % 5.5 % 6.0 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % 6.5 % Tax rate (EBT) 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % 30.0 % NOPAT 2.8 3.8 4.5 5.0 5.7 6.4 6.7 6.9 7.2 7.4 7.7 7.9 8.1 Depreciation 10.4 10.2 10.0 94 97 10.0 10.2 10.5 10.6 10.6 10.5 10.8 11 0 in % of Sales 9.5 % 8.7 % 8.1 % 7.3 % 7.2 % 7.1 % 7.0 % 6.9 % 6.7 % 6.5 % 6.2 % 6.2 % 6.2 % Changes in provisions 1.6 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Change in Liquidity from 0.9 0.9 0.9 - Working Capital -4.2 1.0 0.5 1.4 1.0 1.0 1.0 1.0 1.0 42 - Capex 7.5 7.8 7.8 8.0 8.3 8.7 9.1 9.4 9.8 10.1 10.5 10.8 11.0 Capex in % of Sales 6.8 % 6.7 % 6.3 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % 6.2 % - Other 1.6 1.6 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Free Cash Flow (WACC 9.9 3.6 4.6 5.1 6.1 6.8 7.0 7.1 7.1 7.1 6.9 7.1 3.9 8 Model) PV of FCF 94 31 38 39 43 44 41 39 36 33 30 29 15 48 share of PVs 53 % 35.23 % 48.23 % Model parameter Valuation (m) Derivation of WACC: Derivation of Beta: Present values 2036e 51 **Terminal Value** 48 Debt ratio 22.00 % Financial Strength 1.40 Financial liabilities 28 Cost of debt (after tax) 2.1 % Liquidity (share) 1.30 Pension liabilities 1 0 Market return 8.25 % Cyclicality 1.10 Hybrid capital Risk free rate 2.75 % Transparency 1.30 Minority interest 1 Others 1.30 Market val. of investments 0 Liquidity 3 No. of shares (m) 9.1 WACC 8.10 % Beta 1.28 72 Equity Value Value per share (EUR) 7.97

Sensitivity Value per Share (EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.51	9.1 %	6.06	6.18	6.31	6.45	6.60	6.75	6.92	1.51	9.1 %	4.23	4.97	5.71	6.45	7.19	7.93	8.66
1.40	8.6 %	6.68	6.83	6.98	7.15	7.33	7.53	7.74	1.40	8.6 %	4.76	5.56	6.35	7.15	7.95	8.74	9.54
1.34	8.3 %	7.02	7.18	7.36	7.54	7.74	7.96	8.20	1.34	8.3 %	5.06	5.89	6.72	7.54	8.37	9.20	10.03
1.28	8.1 %	7.39	7.57	7.76	7.97	8.19	8.44	8.71	1.28	8.1 %	5.38	6.24	7.11	7.97	8.83	9.69	10.56
1.22	7.8 %	7.79	7.99	8.20	8.43	8.68	8.96	9.26	1.22	7.8 %	5.73	6.63	7.53	8.43	9.33	10.23	11.13
1.16	7.6 %	8.22	8.44	8.67	8.93	9.22	9.53	9.88	1.16	7.6 %	6.11	7.05	7.99	8.93	9.88	10.82	11.76
1.05	7.1 %	9.18	9.46	9.76	10.09	10.46	10.86	11.31	1.05	7.1 %	6.98	8.02	9.06	10.09	11.13	12.16	13.20

The cyclical components of the business activity and the low liquidity of the share raise capital costs.

Items in the "Others" line adjust for IFRS 16 depreciation on rights of use



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net Income before minorities	-4.6	-0.1	-1.2	-5.7	2.3	3.2	4.0
+ Depreciation + Amortisation	11.7	9.5	9.0	16.6	10.4	10.2	10.0
- Net Interest Income	-1.5	0.8	-1.3	-0.5	-0.7	-0.8	-0.8
- Maintenance Capex	5.2	4.4	4.6	5.9	5.6	5.9	5.9
+ Other	0.0	0.0	0.0	0.0	-1.5	-1.5	-1.5
= Free Cash Flow Potential	3.4	4.3	4.6	5.5	6.3	6.9	7.4
FCF Potential Yield (on market EV)	4.8 %	6.2 %	6.1 %	6.7 %	8.9 %	9.7 %	10.6 %
WACC	8.10 %	8.10 %	8.10 %	8.10 %	8.10 %	8.10 %	8.10 %
= Enterprise Value (EV)	69.9	69.5	75.2	82.5	70.7	70.8	69.9
= Fair Enterprise Value	41.6	52.9	56.3	68.0	78.0	84.8	91.7
- Net Debt (Cash)	23.9	23.9	23.9	23.9	17.6	17.8	16.9
- Pension Liabilities	0.9	0.9	0.9	0.9	2.5	2.5	2.5
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	16.8	28.1	31.5	43.2	57.9	64.5	72.3
Number of shares, average	9.1	9.0	9.0	9.0	9.0	9.0	9.0
= Fair value per share (EUR)	1.85	3.12	3.50	4.80	6.42	7.16	8.02
premium (-) / discount (+) in %					15.7 %	28.9 %	44.5 %
Sensitivity Fair value per Share (EUR)							
11.10 %	0.61	1.52	1.79	2.73	4.04	4.57	5.22
10.10 %	0.94	1.94	2.24	3.27	4.66	5.24	5.95
9.10 %		2.45	2.78	3.93	5.42	6.06	6.83
WACC 8.10 %		3.12	3.50	4.80	6.42	7.16	8.02
7.10 %		3.91	4.34	5.80	7.56	8.40	9.36
6.10 %		4.99	5.49	7.20	9.17	10.14	11.25
5.10 %	4.54	6.51	7.11	9.15	11.40	12.57	13.87

• Capitalised own work is a significant element of the capex.

• FCF-Value-CAGR 2020-2026e: 28%



Valuation 2020 2021 2022 2023 2024e 2025e 2026e Price / Book 0.8 x 0.9 x 0.9 x 1.1 x 0.9 x 0.9 x 0.9 x Book value per share ex intangibles 0.63 0.78 0.60 0.68 1.21 1.44 1.71 EV / Sales 0.9 x 0.8 x 0.8 x 0.7 x 0.6 x 0.6 x 0.6 x EV / EBITDA 4.9 x 4.5 x 4.2 x 9.0 x 7.7 x 7.7 x 5.9 x EV / EBIT 98.7 x 17.5 x 13.1 x 10.8 x n.a. n.a. n.a. EV / EBIT adj.* 44.8 x 23.2 x 23.0 x 14.6 x 11.3 x 10.1 x 8.8 x P / FCF 14.5 x 5.3 x 16.6 x 12.3 x n.a. n.a. n.a. P / E 22.2 x 12.9 x n.a. n.a. n.a. n.a. 16.3 x P / E adj.* n.a. 22.2 x 16.3 x 12.9 x n.a. n.a. n.a. **Dividend Yield** 0.7 % 1.6 % 1.7 % 2.0 % 2.3 % 2.3 % 2.3 % 4.8 % 6.2 % 6.1 % 6.7 % 8.9 % 9.7 % 10.6 % FCF Potential Yield (on market EV)

*Adjustments made for: Adj. figures exclude PPAs and changes to own work capitalized

Company Specific Items							
	2020	2021	2022	2023	2024e	2025e	2026e
order entries	n.a.	n.a.	102.9	0.0	0.0	n.a.	n.a.
book-to-bill	n.a.	n.a.	1.0	0.0	0.0	n.a.	n.a.
order book	n.a.	n.a.	38.2	0.0	0.0	n.a.	n.a.



400 %

350 %

300 %

250 %

200 %

150 %

100 %

50 %

0 %

-50 %

-100 %


Consolidated profit & loss

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	77.6	84.7	98.3	112.6	109.7	116.9	122.9
Change Sales yoy	-14.8 %	9.1 %	16.1 %	14.5 %	-2.6 %	6.6 %	5.1 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	3.7	3.7	3.9	5.7	4.8	5.0	4.7
Total Sales	81.3	88.3	102.3	118.3	114.5	121.9	127.6
Material expenses	35.1	39.1	48.3	51.9	50.4	53.4	55.9
Gross profit	46.1	49.3	53.9	66.4	64.1	68.5	71.7
Gross profit margin	59.5 %	58.2 %	54.9 %	59.0 %	58.5 %	58.6 %	58.3 %
Personnel expenses	31.7	33.6	36.0	40.1	38.7	41.1	42.9
Other operating income	1.7	2.8	3.7	1.7	1.6	1.4	1.5
Other operating expenses	8.4	9.4	11.9	14.1	12.6	13.2	13.8
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	7.8	9.1	9.7	13.9	14.4	15.6	16.5
Margin	10.0 %	10.7 %	9.9 %	12.4 %	13.2 %	13.3 %	13.4 %
Depreciation of fixed assets	2.2	2.2	1.7	2.5	2.4	2.5	2.6
EBITA	5.6	6.8	8.1	11.4	12.0	13.1	13.9
Amortisation of intangible assets	9.5	6.3	7.2	8.0	8.0	7.7	7.4
Goodwill amortisation	0.0	1.0	0.1	6.2	0.0	0.0	0.0
EBIT	-3.9	-0.5	0.8	-2.7	4.0	5.4	6.5
Margin	-5.1 %	-0.6 %	0.8 %	-2.4 %	3.7 %	4.6 %	5.3 %
EBIT adj.	1.6	3.0	3.3	5.6	6.2	7.0	8.0
Interest income	0.1	0.0	0.0	0.1	0.0	0.0	0.0
Interest expenses	0.3	0.3	0.3	0.5	0.6	0.6	0.6
Other financial income (loss)	-1.2	1.1	-1.0	0.0	0.0	0.0	0.0
EBT	-5.4	0.3	-0.6	-3.2	3.3	4.6	5.7
Margin	-7.0 %	0.3 %	-0.6 %	-2.9 %	3.1 %	3.9 %	4.6 %
Total taxes	-0.8	0.4	0.6	2.5	1.0	1.4	1.7
Net income from continuing operations	-4.6	-0.1	-1.2	-5.7	2.3	3.2	4.0
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	-4.6	-0.1	-1.2	-5.7	2.3	3.2	4.0
Minority interest	0.2	0.2	0.2	0.1	0.1	0.1	0.1
Net income	-4.7	-0.3	-1.4	-5.8	2.2	3.1	3.9
Margin	-6.1 %	-0.3 %	-1.4 %	-5.2 %	2.0 %	2.7 %	3.1 %
Number of shares, average	9.1	9.0	9.0	9.0	9.0	9.0	9.0
EPS	-0.52	-0.03	-0.15	-0.65	0.25	0.34	0.43
EPS adj.	-0.52	-0.03	-0.15	-0.65	0.25	0.34	0.43
*Adjustments made for: Adj. figures exclude PPAs and ch	ances to own wor	k canitalized					

Guidance: Sales EUR 105-113m, adj. EBIT EUR 5.0-7.0m. EBIT EUR 3.2-4-6m

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	94.7 %	93.6 %	94.1 %	92.7 %	91.2 %	90.9 %	90.4 %
Operating Leverage	n.a.	-9.6 x	n.a.	n.a.	n.a.	5.1 x	3.9 x
EBITDA / Interest expenses	29.8 x	36.0 x	34.5 x	27.6 x	26.3 x	26.0 x	27.5 x
Tax rate (EBT)	15.5 %	123.9 %	-109.4 %	-75.9 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	n.m.	n.m.	n.m.	n.m.	50.0 %	36.4 %	29.5 %
Sales per Employee	195,458	218,273	248,889	281,488	258,118	275,153	289,186



Consolidated balance sheet



100 %

90 %

80 %

70 %

60 %

50 %

40 %

30 % 20 %


10 %

0 %

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Assets							
Goodwill and other intangible assets	56.8	55.8	55.6	47.4	44.9	42.9	41.2
thereof other intangible assets	20.7	20.2	18.7	36.4	34.1	31.8	29.3
thereof Goodwill	17.5	17.1	17.4	11.0	11.0	11.0	11.0
Property, plant and equipment	5.5	4.8	7.6	8.1	9.3	10.5	11.6
Financial assets	1.5	1.5	0.4	0.4	0.4	0.4	0.4
Other long-term assets	0.0	0.0	0.0	0.0	9.0	9.0	9.0
Fixed assets	63.8	62.1	63.6	56.0	63.7	62.9	62.3
Inventories	13.7	13.4	19.0	23.7	19.9	20.2	19.8
Accounts receivable	14.3	14.1	16.8	12.3	13.5	15.4	16.8
Liquid assets	10.2	9.6	6.8	4.9	11.1	11.0	11.9
Other short-term assets	3.2	4.2	4.3	6.3	6.3	6.3	6.3
Current assets	41.4	41.3	46.8	47.1	50.8	52.8	54.7
Total Assets	105.2	103.4	110.4	103.1	114.5	115.7	117.0
Liabilities and shareholders' equity							
Subscribed capital	9.1	9.1	9.1	9.1	9.1	9.1	9.1
Capital reserve	31.1	31.1	31.1	31.1	31.1	31.1	31.1
Retained earnings	22.9	23.2	21.3	13.9	16.1	19.2	23.1
Other equity components	-0.5	-0.5	-0.5	-0.5	-0.4	-3.5	-6.5
Shareholders' equity	62.6	62.9	61.0	53.6	55.9	56.0	56.7
Minority interest	0.4	0.6	0.8	0.7	0.7	0.7	0.7
Total equity	63.0	63.5	61.8	54.3	56.6	56.7	57.4
Provisions	3.2	2.8	1.2	1.0	5.4	5.4	5.4
thereof provisions for pensions and similar obligations	3.1	2.6	1.1	0.9	2.5	2.5	2.5
Financial liabilities (total)	24.6	21.0	27.2	28.8	28.8	28.8	28.8
Short-term financial liabilities	4.7	3.5	5.5	8.5	8.5	8.5	8.5
Accounts payable	6.0	7.2	9.3	6.8	8.4	9.6	10.1
Other liabilities	8.4	8.8	11.0	12.3	15.3	15.3	15.3
Liabilities	42.2	39.8	48.6	48.8	57.8	59.0	59.5
Total liabilities and shareholders' equity	105.2	103.4	110.4	103.1	114.5	115.7	117.0

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	3.1 x	3.9 x	3.4 x	3.6 x	3.9 x	3.8 x	3.8 x
Capital Employed Turnover	1.0 x	1.1 x	1.2 x	1.4 x	1.4 x	1.5 x	1.6 x
ROA	-7.4 %	-0.4 %	-2.2 %	-10.4 %	3.5 %	4.9 %	6.2 %
Return on Capital							
ROCE (NOPAT)	n.a.	0.1 %	2.0 %	n.a.	3.6 %	4.9 %	5.9 %
ROE	-7.2 %	-0.4 %	-2.3 %	-10.2 %	4.1 %	5.5 %	6.9 %
Adj. ROE	-7.2 %	-0.4 %	-2.3 %	-10.2 %	4.1 %	5.5 %	6.9 %
Balance sheet quality							
Net Debt	17.5	14.0	21.5	24.8	20.1	20.3	19.4
Net Financial Debt	14.4	11.4	20.4	23.9	17.6	17.8	16.9
Net Gearing	27.7 %	22.0 %	34.8 %	45.7 %	35.6 %	35.8 %	33.8 %
Net Fin. Debt / EBITDA	185.7 %	125.4 %	209.4 %	171.8 %	122.1 %	114.1 %	102.6 %
Book Value / Share	6.9	6.9	6.7	5.9	6.1	6.1	6.2
Book value per share ex intangibles	0.6	0.8	0.6	0.7	1.2	1.4	1.7



COMMENT

Published 03.04.2024

7

Consolidated cash flow statement




In EUR m	2020	2021	2022	2023	2024e	2025e	20266
Net income	-4.6	-0.1	-1.2	-5.7	2.3	3.2	4.0
Depreciation of fixed assets	2.2	2.2	1.7	2.5	2.4	2.5	2.6
Amortisation of goodwill	0.0	1.0	0.1	6.2	0.0	0.0	0.0
Amortisation of intangible assets	9.5	6.3	7.2	8.0	8.0	7.7	7.4
Increase/decrease in long-term provisions	0.0	-0.1	-0.5	-0.5	1.6	0.0	0.0
Other non-cash income and expenses	-1.8	-0.2	3.0	1.8	0.0	0.0	0.0
Cash Flow before NWC change	5.3	9.2	10.3	12.2	14.4	13.4	14.0
Increase / decrease in inventory	-1.1	0.3	-5.6	-4.7	3.8	-0.3	0.4
Increase / decrease in accounts receivable	1.2	0.4	-2.9	4.1	-1.2	-1.9	-1.4
Increase / decrease in accounts payable	-0.5	1.2	2.0	-2.5	1.7	1.2	0.5
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-0.4	1.9	-6.4	-3.1	4.2	-1.0	-0.5
Net cash provided by operating activities [1]	4.9	11.1	3.8	9.1	18.6	12.4	13.5
Investments in intangible assets	-5.4	-4.8	-5.1	-6.7	-5.5	-5.7	-5.7
Investments in property, plant and equipment	-1.5	-1.5	-4.9	-2.1	-2.0	-2.1	-2.1
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	-1.5	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-8.5	-5.9	-6.1	-7.9	-7.5	-7.8	-7.8
Change in financial liabilities	1.1	-4.2	1.6	-0.4	0.0	0.0	0.0
Dividends paid	-0.4	-0.4	-0.9	-1.2	-1.2	-1.2	-1.2
Purchase of own shares	-0.5	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-1.4	-1.3	-1.4	-1.5	-3.6	-3.6	-3.6
Net cash provided by financing activities [3]	-1.1	-5.9	-0.7	-3.1	-4.8	-4.8	-4.8
Change in liquid funds [1]+[2]+[3]	-4.7	-0.7	-3.0	-1.9	6.3	-0.2	0.9
Effects of exchange-rate changes on cash	-0.1	0.2	0.1	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	10.2	9.6	6.8	4.9	11.1	11.0	11.9

Financial Ratios

	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	-3.4	3.8	-3.6	-0.3	9.5	3.0	4.1
Free Cash Flow / Sales	-4.4 %	4.5 %	-3.7 %	-0.3 %	8.6 %	2.6 %	3.3 %
Free Cash Flow Potential	3.4	4.3	4.6	5.5	6.3	6.9	7.4
Free Cash Flow / Net Profit	72.2 %	-1501.6 %	258.2 %	5.5 %	424.5 %	97.3 %	105.6 %
Interest Received / Avg. Cash	0.4 %	0.3 %	0.6 %	2.1 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	1.2 %	1.1 %	1.2 %	1.8 %	1.9 %	2.1 %	2.1 %
Management of Funds							
Investment ratio	9.0 %	7.5 %	10.1 %	7.8 %	6.8 %	6.7 %	6.3 %
Maint. Capex / Sales	6.7 %	5.2 %	4.6 %	5.3 %	5.1 %	5.0 %	4.8 %
Capex / Dep	59.6 %	66.1 %	111.1 %	52.5 %	72.1 %	76.5 %	78.0 %
Avg. Working Capital / Sales	24.6 %	21.3 %	19.5 %	19.9 %	19.3 %	16.7 %	16.5 %
Trade Debtors / Trade Creditors	238.7 %	194.7 %	180.9 %	181.8 %	160.7 %	160.4 %	166.3 %
Inventory Turnover	2.6 x	2.9 x	2.5 x	2.2 x	2.5 x	2.6 x	2.8 x
Receivables collection period (days)	67	61	62	40	45	48	50
Payables payment period (days)	62	67	70	48	61	66	66
Cash conversion cycle (Days)	119	86	98	117	85	80	74


CAPEX and Cash Flow in EUR m

Source: Warburg Research





Working Capital



Source: Warburg Research

2020

2021

2022

FCF (m) - Free Cash Flow / Sales

2023 2024e 2025e

8

2026e



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months	
Softing	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005178008.htm	



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	148	70
Hold	47	22
Sell	8	4
Rating suspended	7	3
Total	210	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	49	83
Hold	7	12
Sell	0	0
Rating suspended	3	5
Total	59	100

PRICE AND RATING HISTORY SOFTING AS OF 03.04.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

WARBURG

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables Sander Brockow Industrials **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg **Financial Services** Fabio Hölscher

Automobiles, Car Suppliers **Philipp Kaiser** Real Estate, Construction

Head of Equity Sales. Germany

Marc Niemann

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

Matthias Fritsch

Maximilian Martin

SALES TRADING Oliver Merckel

Head of Sales Trading

United Kingdom

Austria, Poland

Rico Müller

Sales Trading

Sales Trading

Bastian Quast

Carsten Klude

Macro Research

United Kingdom, Ireland

United Kinadom

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-248 sbrockow@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com

+49 40 3282-2678

mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com +49 69 5050-7413 mmartin@mmwarburg.com

> +49 40 3282-2634 omerckel@mmwarburg.com +49 40 3282-2685 rmueller@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com

MACRO RESEARCH

+49 40 3282-2572 cklude@mmwarburg.com

Our research can be found under:

 Warburg Research
 research.mmwarburg.com/en/index.html
 LSEG

 Bloomberg
 RESP MMWA GO
 Capital IQ

 FactSet
 www.factset.com

For access please contact:

 Andrea Schaper
 +49 40 3282-2632
 Kerstin Muthig

 Sales Assistance
 aschaper@mmwarburg.com
 Sales Assistance

Thilo Kleibauer Retail, Consumer Goods Hannes Müller Software, IT Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate, Telco Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

+49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-255 hmueller@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

Rudolf Alexander Michaelis Germany Roman Alexander Niklas Switzerland

Antonia Möller Roadshow/Marketing Charlotte Wernicke Roadshow/Marketing Juliane Niemann

Roadshow/Marketing

DESIGNATED SPONSORING

Marcel Magiera Designated Sponsoring Sebastian Schulz Designated Sponsoring Jörg Treptow Designated Sponsoring

Dr. Christian Jasperneite Investment Strategy +49 40 3282-2649 rmichaelis@mmwarburg.com +49 69 5050-7412 rniklas@mmwarburg.com

+49 69 5050-7417 amoeller@mmwarburg.com +49 40 3282-2669 cwernicke@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2662 mmagiera@mmwarburg.com +49 40 3282-2631 sschulz@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

www.lseg.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com